Akebia Therapeutics (AKBA) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 30.1% versus a loss of 72.3%. Over five years, AKBA leads with a -71.9% price change compared with -94.5% for RNAC. Akebia Therapeutics is the larger company by market cap ($222.0 million vs $213.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | RNAC |
|---|---|---|
| Share price | $0.8011 | $7.06 |
| Market cap | $221.99M | $213.45M |
| 1-day change | -1.68% | +3.45% |
| YTD return | -50.24% | -2.15% |
| 1-year return | -72.28% | -30.15% |
| 5-year return | -71.89% | -94.49% |
| EPS (TTM) | $-0.12 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $11.00 |
| 52-week low | $0.8011 | $5.60 |
| Distance from 52-week high | -74.97% | -35.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +389.33% | +377.25% |
| Average volume | 6.18M | 133.51K |
| Shares outstanding | 277.11M | 30.26M |
| Employees | 194 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNAC has outperformed AKBA by 42.1 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
AKBA vs RNAC FAQ
Which is bigger, Akebia Therapeutics or Cartesian Therapeutics?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $221.99M compared with $213.45M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, AKBA or RNAC?
RNAC returned -30.15% over the past 12 months, compared with -72.28% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.